These 3 Risky Stocks Could Be Sitting on 100% Upside

Red Cat (RCAT) analysts predict 115% upside to $18 per share despite rising expenses. Taysha (TSHA) advances TSHA-102 for Rett syndrome, awaiting FDA application. Solaris (SLSR) eyes 118% gain if Warintza copper project succeeds, pending feasibility study.

Original reporting
Published Sep 9, 2026, 3:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 4:22 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
These 3 Risky Stocks Could Be Sitting on 100% Upside — source image
Decision brief

The 30-second read

$RCATBullishLow
01

Why it matters

No new primary data; the piece serves as a speculative watchlist.

02

Market read

Limited trading relevance; primarily opinion‑driven upside speculation.

03

What to watch

Regulatory delays, financing constraints, and market liquidity risks.

Relevance 4/10Novelty 2/10Timing: general outlook

Background

The article lists three small‑cap stocks deemed risky but with potential upside, citing analyst price targets and development milestones.

Company-level read

Ticker impact

$RCATBullishLow confidence
Context

Analysts estimate RCAT could rise 115% to $18 amid rising expenses.

Expected impact

Modest upside if target gains traction.

Evidence & confidence

No new catalyst; price target reflects opinion, not fresh data.

$TSHABullishLow confidence
Context

TSHA is moving TSHA-102 toward an FDA BLA and awaiting REVEAL study results.

Expected impact

Potential sharp rally on favorable trial readout.

Evidence & confidence

Article only recaps ongoing development; no new trial data released.

$SLSRBullishLow confidence
Context

SLSR's upcoming feasibility study for the Warintza copper project may boost shares 118% if results are strong.

Expected impact

Possible upside if study confirms project economics.

Evidence & confidence

Speculative outlook without new study results; opinion‑driven.

Market effects

Highlights risk‑reward in biotech and copper sectors.

Limited; focuses on US‑listed micro‑caps.

Low; niche speculative interest only.

Counterpoint

These stocks may remain overvalued despite upside narratives.

Key entities

  • Red Cat Holdings

    NASDAQ‑listed biotech/health company.

  • Taysha Gene Therapies

    NASDAQ‑listed gene‑therapy developer.

  • Solaris Resources

    NYSEAMERICAN‑listed copper miner.

Related articles

$RCATHighAI 9/10

Why Is Red Cat Holdings Stock Falling 25.8% in Pre-Market Trading?

Red Cat Holdings (RCAT) shares fell 25.8% in pre-market trading after reporting Q3 revenue of $11.77M, missing estimates by 72%. The company withdrew its 2026 revenue target and declined to provide Q4 guidance, citing uncertainties. Adjusted net loss was $0.26 per share, worse than expected. Gross profit margin was 0.6%, and operating losses increased to $43.4M.

$RCATHighAI 9/10

Why is Red Cat Holdings stock plummeting today?

Red Cat Holdings stock fell 25.8% premarket after reporting Q3 revenue of $11.77M, missing estimates by 72% and withdrawing its 2026 revenue target. The company also reported a wider-than-expected adjusted net loss of $0.26 per share and no Q4 guidance due to defense funding uncertainties. Piper Sandler cut its price target to $6.

$RCATMed

Red Cat Shares Fall 25% After Withdrawing 2026 Revenue Target

Red Cat Holdings (RCAT) shares dropped 25% in extended trading after withdrawing its 2026 revenue target due to slower funding and contract awards. Q3 revenue rose 22% to $11.77M but missed estimates. The company cited funding and delivery uncertainties, with operating expenses doubling and gross profit falling to $65K. Cash burn was $156.84M over nine months, though it held $242.73M in cash at quarter-end.